Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled time : 06:00 save search
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $94.25 1.67% -2.18% 480
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Published: 2022-05-23 (Crawled : 06:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
hypertension positive phase 3
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its RSV Vaccine Candidate in Older Adults
Published: 2022-04-20 (Crawled : 06:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
vaccine trial phase 3 order
Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease36-Month Results of Phase 3 Trial in Chronic Low Back Pain Presented at 2022 Biotech Showcase
Published: 2022-01-12 (Crawled : 06:00) - biospace.com/
MESO | $6.0 8.5% 7.37% 620K
|
Health Technology
|
| O: 6.4%
H: 0.0%
C: -3.21%
phase 3
Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-14 (Crawled : 06:00) - biospace.com/
ATRA | $0.7186 3.04% 3.13% 0
|
Health Technology
|
| O: -4.53%
H: 4.22%
C: 2.01%
cel ema trial therapeutics positive results tab-cel positive results phase 3 iot
Adocia’s partner Tonghua Dongbao Receives Clearance to Start Ultra-Rapid Insulin BioChaperone® Lispro Phase 3 Trial to Treat Type 1 and Type 2 Diabetes in China
Published: 2021-10-14 (Crawled : 06:00) - globenewswire.com
LLY | News | $745.69 1.96% 0.04% 1.4M
|
Health Technology
|
| O: 0.24%
H: 0.6%
C: -0.14%
diabetes china insulin phase 3 trial clearance
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
Published: 2021-10-04 (Crawled : 06:00) - globenewswire.com
GLPGF | News | $35.5157 71.75% 4.8K
|
Health Technology
|
| O: -4.52%
H: 0.0%
C: 0.0%
GILD | $67.03 0.12% 0.12% 15K
|
Health Technology
|
| O: -1.09%
H: 1.21%
C: -0.94%
GLPG | News | $29.45 1.31% 1.36% 16K
|
Health Technology
|
| O: -1.82%
H: 0.04%
C: -1.29%
disease phase 3 enroll
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
Published: 2021-09-09 (Crawled : 06:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -1.54%
H: 0.23%
C: -0.59%
treatment phase 3
Everest Medicines Announces Approval of Clinical Trial Application by China NMPA for Phase 3 Trial of Xerava(TM) for Community-Acquired Bacterial Pneumonia
Published: 2021-08-05 (Crawled : 06:00) - prnewswire.com
LJPC | $6.22 0.0%
|
Health Technology
|
| O: 6.5%
H: 10.34%
C: 8.49%
acquired china phase 3 trial approval
Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA
Published: 2021-08-03 (Crawled : 06:00) - globenewswire.com
NVS | News | $97.28 2.27% 1.21% 3.5M
|
Health Technology
|
| O: 0.3%
H: 0.17%
C: 0.17%
phase 3 trial order
Idorsia initiates the Phase 3 registration study with selatogrel for the treatment of acute myocardial infarction
Published: 2021-06-28 (Crawled : 06:00) - globenewswire.com
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.23%
H: 1.84%
C: -1.61%
treatment phase 3
Sanofi and Translate Bio Initiate Phase 1 Clinical Trial of mRNA Influenza Vaccine
Published: 2021-06-22 (Crawled : 06:00) - globenewswire.com
TBIO | $0.3235 2.63% 1.5% 140K
|
Health Technology
|
| O: 0.0%
H: 10.57%
C: 10.25%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.57%
H: 0.25%
C: -0.04%
phase 1 vaccine influenza trial phase 2 phase 3
Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
Published: 2021-06-17 (Crawled : 06:00) - prnewswire.com
AZN | News | $70.85 1.03% 1.02% 490K
|
Health Technology
|
| O: -0.6%
H: 0.69%
C: 0.5%
phase 1 cancer colorectal cancer trial phase 3 phase 2 enroll
REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2
Published: 2021-06-16 (Crawled : 06:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.15%
H: 0.3%
C: -0.78%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 0.7%
H: 2.12%
C: -1.43%
covid casirivimab phase 3 trial sars-cov-2
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Published: 2021-05-27 (Crawled : 06:00) - globenewswire.com
JNJ | News | $149.56 0.3% 0.03% 140K
|
Health Technology
|
| O: 0.11%
H: 0.54%
C: -0.27%
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.5%
H: 0.32%
C: -1.27%
covid vaccine phase 3 covid-19
Phase 3 Prevention Trial Showed 81% Reduced Risk of Symptomatic SARS-CoV-2 Infections with Subcutaneous Administration of REGEN-COV™ (casirivimab with imdevimab)
Published: 2021-04-12 (Crawled : 06:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.33%
H: 0.12%
C: -0.69%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -1.86%
risk phase 3 trial casirivimab injection sars-cov-2 infections
Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19
Published: 2021-04-12 (Crawled : 06:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.6M
|
Health Technology
|
| O: -0.33%
H: 0.12%
C: -0.69%
REGN | News | $907.32 0.8% 0.74% 220K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -1.86%
covid treatment phase 3 trial casirivimab injection infections
Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
Published: 2021-04-06 (Crawled : 06:00) - globenewswire.com
DVAX | $11.76 -0.68% -0.77% 1.4M
|
Health Technology
|
| O: 2.13%
H: 4.49%
C: 0.7%
covid phase 1 positive vaccine vla2001 phase 3 phase 2 covid-19
Gainers vs Losers
| 77% | 23% |
Top 10 Gainers
AGBA | $2.97 137.6% 54.87% 66M
|
Finance
HKIT | $1.33 30.39% 27.14% 39K
|
Technology Services
VRT 4 | $79.17 4.08% 19.36% 6.6M
|
Electronic Technology
FOA 4 | $0.5144 -8.16% 15.43% 20
|
Finance and Insurance
EAST | $1.0835 16.17% 15.21% 100
|
Commercial Services
BOF | $1.17 6.36% 14.73% 15K
|
TSLA | News | $144.68 1.85% 9.01% 93M
|
Consumer Durables
BNED | $0.2064 2.64% 8.96% 1.4M
|
Retail Trade
HLTH | $0.15 6.38% 7.84% 21K
|
LRN 4 | $58.2 0.17% 7.56% 950K
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.